Chronic hepatitis B is caused by the mutation of hepatitis B virus (HBV) that inhibits the synthesis of hepatitis B virus e antigen (HbeAg) [1], which is mainly inflammatory lesions of the liver and can cause multi-organ damage, and has become a serious threat to human health worldwide, and is also one of the most prevalent and dangerous infectious diseases in China. HBV mainly affects children and young adults, and some patients can be transformed into cirrhosis and liver cancer. At present, the clinical treatment of chronic hepatitis B is mainly antiviral therapy, which can inhibit or suspend the replication of virus, reduce the damage of liver cells, delay the natural course of chronic hepatitis B, and prevent the occurrence of cirrhosis and liver cancer. Nucleoside (acid) analogues (lamivudine, adefovir, entecavir, etc.) are one of the main drugs used in clinical antiviral therapy, and have been the hotspots of antiviral drug research in recent years, with rapid progress. Because of its fast onset of action, cheap, convenient oral administration and no specific adverse reactions, it is accepted by many patients with chronic hepatitis B. It has become the “favorite” in the market of hepatitis treatment drugs in recent years; however, in clinical use, it is found that some patients, due to the lack of relevant knowledge, poor compliance with medication, unauthorized discontinuation of medication or do not pay attention to However, in the clinical use, we found that some patients, due to the lack of knowledge and poor compliance with the medication, discontinued the medication or did not pay attention to the clinical follow-up after discontinuation, resulting in serious consequences. In view of this situation, since 2009, we have implemented systematic health education guidance for patients with chronic hepatitis B treated with antiretroviral therapy, and received good results, which are summarized as follows. 1, clinical data 1.1 General data From January 2009 to October 2010, there were 160 patients with chronic hepatitis B undergoing oral nucleotide analog antiviral therapy in our department. The diagnosis of chronic hepatitis B was in accordance with the revised diagnostic criteria of the National Academic Conference on Viral Hepatitis and Liver Diseases in 2000 [3]. There were 128 cases of men and 32 cases of women, aged 18 to 56 years. There were 55 cases on lamivudine, 40 cases on adefovir, 47 cases on entecavir, and 18 cases on telbivudine. 1.2 Treatment The commonly used antiviral drugs were adefovir (Hovirix), lamivudine (Heptin), entecavir (Boludin), and telbivudine (Sulbivir) at a therapeutic dose of 1 capsule daily, taken regularly for at least 2-3 years. 1.3 Establish medication monitoring and follow-up records The physician will provide guidance to each patient at the time of consultation, detailing the purpose of medication, treatment goals, medication precautions, discontinuation criteria, and review time, etc., and record the condition in the outpatient medical record. The nurse records the basic information of patients, establishes personal medication files, unified storage of medical records, issues relevant information, and urges patients to use medication on time. 2. Health education content 2.1 Pre-medication education (1) Let patients know that treatment of hepatitis B requires careful use of medication, and that they must strictly grasp the therapeutic applicability of antiviral treatment drugs, so that they fully understand the importance and necessity of treatment and take the initiative to cooperate with treatment. At the same time, inform patients of the long course of antiviral therapy and the high cost of treatment, so that they can be fully prepared and establish the concept that they must adhere to long-term medication. (2) Let patients understand the therapeutic characteristics of antiviral drugs, and explain to them that most people can tolerate long-term nucleoside (acid) analogue antiviral drugs well before using them, but any drug has adverse effects. Lamivudine has a better safety profile; adefovir has been reported to cause kidney damage when administered at higher doses (50mg/d), so it should be used with caution in patients with combined kidney disease; tebivudine can cause muscle damage (manifested as elevated creatine kinase, accompanied by muscle pain and even rhabdomyolysis in severe cases), so those with combined myositis should avoid using the drug. Therefore, patients should be reminded to notify their doctors of any discomfort that may occur during the course of drug administration; patients should be instructed to correctly understand the possibility of virus mutation and recurrence, so that they should neither take it lightly nor be overly nervous. 2.2 Education in medication administration (1) Never take medication on time: advise patients to take medication at a fixed hour every day, make it a habit, avoid missing doses, and make up for it in case of missing doses; (2) Never reduce or stop medication without authorization: advise patients to take medication under the guidance of a specialist, and not to stop medication on their own, especially at the end of the course of treatment when the reduction must be confirmed by a doctor; (3) Regular monitoring and follow-up: urge patients to review regularly, take medication for the first The liver and kidney function, blood routine and HBV-DNA quantification should be rechecked after the first month of medication, and every 3 months after the condition stabilizes, and ultrasound should be done once every 6 months. 2.3 Post-discontinuation education After treatment, chronic hepatitis B can be discontinued under the guidance of doctors if the criteria for drug discontinuation are met. The drug can be discontinued after checking once every 6 months and meeting the standard twice in a row or more than 1 year. Liver function, kidney function, hepatitis B and HBV-DNA quantification should continue to be monitored every 6 months to prevent relapse of the disease. The patient should avoid drinking alcohol, using hepatotoxic drugs and other factors that are not good for the liver. 3 , Summary In conclusion, education and guidance on medication use is one of the skills that must be mastered in modern nursing, aiming to help patients to acquire knowledge, establish beliefs and establish behaviors, and to produce results through this link, so the effectiveness of education depends crucially on the patient [2]. And in the process of hepatitis B treatment, the patient’s compliance is very important, otherwise, once the efficacy is lost, it will not only affect the work, but also aggravate their own condition and bring great mental and economic pressure to the patient and his family, which must be given enough attention. Health education interventions directly affect patients’ attitudes toward medical care, correcting poor medication habits, improving correct understanding of liver disease, and working closely with families are effective measures to control the continued spread of viral hepatitis B.